acute pyelonephritis
Information
- Disease name
- acute pyelonephritis
- Disease ID
- DOID:559
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04682834 | Available | Expanded Access Use of Sulopenem Etzadroxil/Probenecid for Complicated Urinary Tract Infection | |||
| NCT01928433 | Completed | Phase 2 | Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis | December 2012 | October 2015 |
| NCT02034851 | Completed | Dexamethasone Administration in 1st Episode of Febrile Urinary Tract Infection | April 2013 | June 2019 | |
| NCT02166476 | Completed | Phase 3 | Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP | November 20, 2014 | April 28, 2016 |
| NCT02168946 | Completed | Phase 3 | Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults | July 2014 | July 21, 2017 |
| NCT02420366 | Completed | Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae | May 2014 | January 2015 | |
| NCT02486627 | Completed | Phase 3 | A Study of Plazomicin Compared With Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP) | January 11, 2016 | September 22, 2016 |
| NCT02753946 | Completed | Phase 2/Phase 3 | Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections | April 2016 | May 30, 2017 |
| NCT03445195 | Completed | Phase 2 | Evaluation of Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infections | January 17, 2018 | May 17, 2018 |
| NCT03477422 | Completed | Phase 3 | CSE-1034 (Ceftriaxone+ Sulbactam+ EDTA) Compared to Meropenem in Complicated Urinary Tract Infections (cUTIs) Caused by ESBL Producing Gram Negative Bacteria | January 11, 2014 | May 8, 2017 |
| NCT06141395 | Completed | NGS-Based Assay of Blood Samples of Sepsis Patients for Rapid Bacterial Identification | November 16, 2023 | March 14, 2024 | |
| NCT03757234 | Completed | Phase 2 | IV or IV/PO Omadacycline vs. IV/PO Levofloxacin for the Treatment of Acute Pyelonephritis | November 19, 2018 | July 24, 2019 |
| NCT03788967 | Completed | Phase 3 | Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) | June 3, 2019 | May 27, 2020 |
| NCT03840148 | Completed | Phase 3 | Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections | August 7, 2019 | December 14, 2021 |
| NCT04667195 | Completed | Clinical Characteristics of Acutely Hospitalized Adults With Acute Pyelonephritis | March 1, 2021 | June 1, 2022 | |
| NCT04686318 | Completed | Accuracy of Infection Biomarkers in the Investigation of Patients With Suspected Acute Pyelonephritis | March 1, 2021 | June 1, 2022 | |
| NCT04882085 | Completed | Phase 4 | Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults | August 26, 2021 | August 31, 2023 |
| NCT01096849 | Completed | Phase 2 | A Study of Plazomicin Compared With Levofloxacin for the Treatment of Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP) | July 13, 2010 | April 3, 2012 |
| NCT03630081 | Not yet recruiting | Phase 3 | Study of Cefepime-tazobactam (FEP-TAZ) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) | January 2024 | February 2026 |
| NCT05905055 | Recruiting | Phase 3 | P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales | September 22, 2023 | February 2025 |
| NCT05887908 | Recruiting | Phase 3 | Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis | May 23, 2023 | November 2024 |
| NCT06059846 | Recruiting | Phase 3 | A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) | December 21, 2023 | December 2025 |
| NCT05674032 | Recruiting | Bacterial Metallophores in the Diagnosis of Acute Pyelonephritis | June 24, 2020 | December 2024 | |
| NCT04654507 | Recruiting | Phase 3 | Efficacy of Corticosteroids in Reducing Renal Scarring in Acute Pyelonephritis in Children | March 3, 2021 | December 2024 |
| NCT04979806 | Recruiting | Phase 3 | Study of Cefepime-zidebactam (FEP-ZID) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) | August 28, 2022 | May 2024 |
| NCT02537847 | Unknown status | Phase 2 | Sitafloxacin and Ertapenem Treatment for Acute Pyelonephritis Caused by Escherichia Coli | November 2012 | May 2016 |
| NCT05060419 | Unknown status | Phase 2 | Meropenem-FL058 Phase 2 Study in the Treatment of Complicated Urinary Tract Infections | October 8, 2021 | August 31, 2022 |
- Disase is a (Disease Ontology)
- DOID:11400
- Cross Reference ID (Disease Ontology)
- ICD10CM:N10
- Cross Reference ID (Disease Ontology)
- ICD9CM:590.1
- Cross Reference ID (Disease Ontology)
- NCI:C123215
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:155862004
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0520575